CNSide Diagnostics now licensed in 48 U.S. States covering over 90% of the U.S. populationHOUSTON, Dec. 11, 2025 (GLOBE ...

Basel: Roche has announced the CE Mark for its cobas BV/CV (Bacterial Vaginosis/Candida Vaginitis) assay to accurately identify specific bacteria and yeast responsible for BV and CV in ...

In this interview, Dr. Gary Pestano and Dr. Prithwish Pal discuss the advantages ddPCR offers in molecular residual disease ...

The global lateral flow assay (LFA) components market is poised for significant growth, projected to reach USD 486.2 million ...

No one's crossed the finishing line yet, but drug developer Nyrada is leading the Great Biotech Regatta of 2025 with close to ...

FDA expands labels for Roche's PATHWAY HER2 (4B5) test* and VENTANA HER2 Dual ISH DNA Probe Cocktail, which can now be used to identify HER2-positive metastatic breast cancer patients that could be ...

Basel, 9 December 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the CE Mark for its cobas® BV/CV (Bacterial Vaginosis/Candida Vaginitis) assay to accurately identify specific bacteria and ...

ICMR funds new clinical trial to test effective dosing strategy of high-cost cancer drug PARP inhibitor: Our Bureau, Mumbai Monday, December 15, 2025, 17:10 Hrs [IST] Funded by th ...

"We are strategically building the team to bolster our capabilities as we scale up our laboratory operations to address the largely untapped $6billion+ U.S. addressable market for CNSide cerebrospinal ...

The Every Woman study- Low and low-middle-income country edition, published  in the prestigious journal The Lancet on 11th ...

Discover what the next wave of AI-assisted drug discovery looks like and how it can help biotech - the AI and physics combo.

Explore the shipping of organoid models with Atelerix and Cherry Biotech's innovative collaboration for improved transport ...